Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) FCF Margin (2016 - 2025)

Historic FCF Margin for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to 38.98%.

  • Ironwood Pharmaceuticals' FCF Margin rose 282100.0% to 38.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.96%, marking a year-over-year decrease of 127600.0%. This contributed to the annual value of 29.43% for FY2024, which is 119400.0% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported FCF Margin of 38.98% as of Q3 2025, which was up 282100.0% from 17.68% recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' FCF Margin registered a high of 82.95% during Q1 2021, and its lowest value of 17.68% during Q2 2025.
  • For the 5-year period, Ironwood Pharmaceuticals' FCF Margin averaged around 46.54%, with its median value being 48.42% (2025).
  • In the last 5 years, Ironwood Pharmaceuticals' FCF Margin skyrocketed by 302000bps in 2021 and then plummeted by -530700bps in 2025.
  • Ironwood Pharmaceuticals' FCF Margin (Quarter) stood at 55.02% in 2021, then skyrocketed by 34bps to 73.89% in 2022, then crashed by -59bps to 30.3% in 2023, then plummeted by -45bps to 16.8% in 2024, then soared by 132bps to 38.98% in 2025.
  • Its FCF Margin stands at 38.98% for Q3 2025, versus 17.68% for Q2 2025 and 48.42% for Q1 2025.